Back to News
Market Impact: 0.18
Aclaris (ACRS) Soars 6.0%: Is Further Upside Left in the Stock?
Source: zacks.com
Market Technicals & FlowsAnalyst EstimatesHealthcare & Biotech
Aclaris Therapeutics shares surged in the latest trading session on above-average volume. However, the article cautions that recent earnings-estimate revision trends may not support further near-term price gains, creating a mixed outlook for the stock.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mixed
Sentiment Score
0.05
Ticker Sentiment
ACRS0.15
More News
- Wall Street Punishes Tech Stocks on Earnings Misses
- Intel’s stock crashes, knocking $12B from government’s stake
- Intel plunged 28.6% for its worst drop since 1974 — and the AI sell-off gave the S&P 500 its worst day since June
- Tech sell-off drives US markets down by nearly $1tn after subpar earnings reports
- Tech giants need legacy businesses to keep growing as they pour trillions into the AI buildout
- S&P 500 Price Forecast: AI Spending Fears Put 7,500 Support at Risk